What is claimed is:

1. A method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a $5-HT_{1F}$ receptor agonist which activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates each of the human $5-HT_{1A}$, $5-HT_{1D}$, $5-HT_{2A}$, $5-HT_{2C}$, $5-HT_3$, $5-HT_4$, and $5-HT_7$ receptors.

2. The method of claim 1, wherein the $5-HT_{1F}$ receptor agonist additionally activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates each of the $5-HT_{1B}$, $5-HT_{1E}$, $5-HT_{2B}$, $5-HT_{5A}$, $5-HT_{5B}$, and $5-HT_6$ receptors.

3. The method of claim 1, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates any human α_2 adrenoceptor or any human β adrenoceptor.

4. The method of claim 1, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates the human histamine H_1 and H_2 receptors.

5. The method of claim 1, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates the human dopamine D_1, D_2, D_3, and D_5 receptors.

6. The method of claim 1, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it

activates the human α_{1A} adrenoceptor and the human α_{1B} adrenoceptor.

7. The method of claim 1, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 50-fold more than it activates each of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_{3}, 5-HT_{4}, and 5-HT_{7} receptors.

8. The method of claim 7, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 50-fold more than it activates each of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, and 5-HT_{6} receptors.

9. The method of claim 7, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates any human α_2 adrenoceptor or any human β adrenoceptor.

10. The method of claim 7, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human histamine H_1 and H_2 receptors.

11. The method of claim 7, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human dopamine D_1, D_2, D_3, and D_5 receptors.

12. The method of claim 7, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human α_{1A} adrenoceptor and the human α_{1B} adrenoceptor.

13. The method of claim 7, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 100-fold more than it activates each of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_3, 5-HT_4, and 5-HT_7 receptors.

14. The method of claim 13, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 100-fold more than it activates each of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, and 5-HT_6 receptors.

15. The method of claim 13, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates any human α_2 adrenoceptor or any human β adrenoceptor.

16. The method of claim 13, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human histamine H_1 and H_2 receptors.

17. The method of claim 13, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human dopamine D_1, D_2, D_3, and D_5 receptors.

18. The method of claim 13, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human α_{1A} adrenoceptor and the human α_{1B} adrenoceptor.

19. The method of claim 13, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 200-fold more than it activates each of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_3, 5-HT_4, and 5-HT_7 receptors.

20. The method of claim 19, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 200-fold more than it activates each of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, and 5-HT_6 receptors.

21. The method of claim 19, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates any human α_2 adrenoceptor or any human β adrenoceptor.

22. The method of claim 19, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human histamine H_1 and H_2 receptors.

23. The method of claim 19, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human dopamine D_1, D_2, D_3, and D_5 receptors.

24. The method of claim 19, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human α_{1A} adrenoceptor and the human α_{1B} adrenoceptor.